Results 111 to 120 of about 847 (163)

Integrating gepants into clinical practice for the acute treatment of migraine. [PDF]

Headache
Lipton RB, Dodick DW, Davis L, Nahas SJ, Goadsby PJ.   +4 more
europepmc   +1 more source

Improvements in Patient-Reported Outcome Measures Through 64 Weeks' Rimegepant Treatment for Migraine: Analysis of a Randomized Controlled Trial with Open-Label Extension. [PDF]

J Pain Res
Lipton RB, Buse DC, Martin VT, Semel D, Cappelleri JC, Thiry A, Abraham L, Fullerton T.   +7 more
europepmc   +1 more source

CGRP-Targeting Therapies in Vestibular Migraine: A Synthesis of Observational Evidence with Direction-of-Effect Analysis. [PDF]

Med Sci (Basel)
Ciubotaru A, Mastaleru A, Schreiner TG, Grosu C, Alexa D, Oancea A, Vamanu A, Roceanu AM, Cucu AI, Pana BI, Cozma RS, Olariu R, Dan Iulian C, Ignat EB.   +13 more
europepmc   +1 more source

Endothelial senescence drives intrinsic skin aging via the neuroimmune CGRP-mast cell axis in mice. [PDF]

Commun Biol
Wicaksono SA, Ryanto GRT, Suzuki Y, Hara T, Ikeda K, Fukumoto T, Hirata KI, Otake H, Emoto N.   +8 more
europepmc   +1 more source

Abstracts from the 19th European Headache Congress (EHC). [PDF]

J Headache Pain
europepmc   +1 more source

Atogepant for the Preventive Treatment of Migraine

New England Journal of Medicine, 2021
Atogepant is an oral, small-molecule, calcitonin gene-related peptide receptor antagonist that is being investigated for the preventive treatment of migraine.In a phase 3, double-blind trial, we randomly assigned adults with 4 to 14 migraine days per month in a 1:1:1:1 ratio to receive a once-daily dose of oral atogepant (10 mg, 30 mg, or 60 mg) or ...
Jessica Ailani, Richard B. Lipton, Peter Goadsby   +2 more
exaly   +5 more sources

Atogepant: an emerging treatment for migraine

Expert Opinion on Pharmacotherapy, 2022
Until recently, only nonspecific and not always well-tolerated medications were available for migraine prophylaxis. Currently, specific drugs such as calcitonin gene-related peptide (CGRP) monoclonal antibodies and second-generation gepants are marketed for migraine treatment.
Rustichelli, Cecilia, Avallone, Rossella, Ferrari, Anna   +2 more
openaire   +3 more sources

Atogepant: First Approval

Drugs, 2021
Atogepant (Qulipta™) is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by AbbVie for the prophylaxis of migraine. In September 2021, atogepant was approved in the USA for the preventive treatment of episodic migraine in adults.
Emma D Deeks (4985300)
openaire   +3 more sources